Quarterly report pursuant to Section 13 or 15(d)

LICENSE AGREEMENT WITH INSERM (Details Narrative)

v3.21.2
LICENSE AGREEMENT WITH INSERM (Details Narrative)
Feb. 11, 2021
USD ($)
License Agreement [Member] | Inserm [Member] | Oxytocin-based Therapeutics [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Sales milestones $ 400,000